Menopause and peptides: what does the research show?

First, hormone therapy and peptides are not the same thing

Oestrogen and progesterone are steroid hormones, not peptide hormones. (Female reproductive physiology) Menopausal hormone therapy, often called MHT or HRT, has an established role in managing symptoms such as hot flushes and night sweats. (AMS hormone-therapy guide)

There are also non-hormonal management options, and the right approach depends on symptoms, preferences and medical history. (NICE menopause guidance) Peptide research is an additional subject to understand, not a reason to overlook established menopause care.

Hot flushes: peptide signalling led to a different kind of medicine

Fezolinetant blocks the neurokinin-3 receptor, part of a brain-signalling pathway involved in temperature regulation. (Fezolinetant review, 2023) It is a small-molecule, non-hormonal medicine, not a peptide preparation. (Fezolinetant review, 2023)

In Australia, Veoza, the fezolinetant medicine, is approved for moderate to severe menopausal vasomotor symptoms, meaning hot flushes and night sweats. (TGA Veoza decision) It also has a liver-injury warning and requires liver-function monitoring, so non-hormonal does not mean risk-free. (TGA liver-safety update)

This is a useful example of how understanding a signalling pathway can lead to a targeted medicine. It does not mean that adding or buying the signalling peptide would have the same effect.

Bone health: a genuine peptide-medicine example

Teriparatide is a 34-amino-acid fragment of human parathyroid hormone, studied for its bone-forming effects. (Teriparatide product information) Its pivotal trial involved 1,637 postmenopausal women and found fewer new spinal and non-spinal fragility fractures than with placebo. (Teriparatide product information)

An Australian teriparatide indication covers postmenopausal osteoporosis when other agents are unsuitable and fracture risk is high. (TGA teriparatide indication) This is evidence for a diagnosed bone condition and a regulated medicine, not a routine supplement for everyone after menopause.

Sexual wellbeing: desire is not the same as dryness

PT-141, also called bremelanotide, is the active ingredient in the US medicine Vyleesi for a specific low-desire disorder in premenopausal women. (Current US Vyleesi label) Its current US label explicitly says it is not indicated for postmenopausal women or for enhancing sexual performance. (Current US Vyleesi label)

The same label includes cardiovascular contraindications and common adverse effects such as nausea, flushing and headache. (Current US Vyleesi label) Those facts matter when separating a sexual-health medicine from a general wellbeing claim.

Kisspeptin is another research topic: a 2022 randomised crossover study involved 40 premenopausal women with low sexual desire, of whom 32 completed the study. (Thurston et al., 2022) It found changes in sexual brain processing and some related responses, but did not establish a long-term treatment for postmenopausal symptoms. (Thurston et al., 2022)

Vaginal dryness and painful sex are different treatment questions from low desire. (NICE menopause guidance) Menopause guidance includes established options for vaginal symptoms, with suitability assessed according to individual medical history. (NICE menopause guidance)

Skin: where GHK-Cu findings fit

A 2026 cosmetic study tested a cream combining GHK-Cu with a ferment extract, with 30 participants completing the human study. (Wang et al., 2026) It reported changes in selected wrinkle, hydration and skin-barrier measurements. (Wang et al., 2026)

The human study had no placebo group, did not isolate GHK-Cu's contribution and did not define participants by menopausal status. (Wang et al., 2026) That makes it formulation-specific cosmetic research, not evidence that GHK-Cu treats menopause or works the same way in another preparation.

How to read a menopause-peptide claim

Ask what the claim is actually about: hot flushes, body weight, fractures, desire, vaginal symptoms or skin appearance. A result in one category should not be treated as proof of benefit in all the others.

The TGA says human evidence should be relevant to the specific peptide, formulation, route and condition being treated. (TGA evidence guidance) It also distinguishes approved peptide medicines from unapproved peptide products that have not been assessed for safety, quality or effectiveness. (TGA peptide-product overview)

A familiar molecule name therefore does not make a research-labelled vial equivalent to an approved medicine. The exact product and clinical context matter.

The clear takeaway

There is useful science to explore: targeted hot-flush medicines, weight-management research, established bone medicines and emerging sexual-health and skin findings. (TGA Veoza decision) (Hurtado et al., 2024) (Teriparatide product information) (Thurston et al., 2022) (Wang et al., 2026) They answer different questions rather than adding up to one proven menopause-peptide regimen.

A practical starting point is to identify the symptom or health goal, then discuss options with a clinician familiar with menopause care. (NICE menopause guidance) That keeps the conversation positive and specific, while leaving room for new research to earn its place.